Skip to main content

Advertisement

SpringerLink
Log in

Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response

  • Invited Review
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Prevalence of advanced genitourinary cancer is high considering approximately 70,000 patients die annually of prostate, bladder and kidney cancer in the United States. Treatment is non-curative but along with the aim of relieving symptoms and improving quality of life, patients and doctors are driven by the goal of prolonging life. In modern urological practice, with the ever increasing number of novel therapies, clinical benefit to patients has to be measured by evaluating the trial endpoints of response and survival against adverse events. This is especially true as the population with advanced cancer is increasingly older and co-morbid. Currently, we are in a time of exponential drug development, innumerable registered trials and a vast amount of expenditure on pharmacological cancer treatment. In this era of financial uncertainty, it is even more important for clinicians to objectively assess the benefit of these expensive, moderately effective treatments that still have associated adverse sequelae. We aim to highlight the pivotal data available and put into context the survival benefit we can currently achieve with the pharmacological treatment of advanced genitourinary cancer, allowing us to critically judge whether a potentially toxic systemic treatment is worthwhile or whether it is better to defer to best supportive care. The figures presented are from the key publications that form the basis of international guideline recommendations and are the standard that newly developed treatments must emulate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. Sullivan R, Peppercorn J, Sikora K et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12:933–980

    Article  PubMed  Google Scholar 

  3. Chang SS (2007) Treatment options for hormone-refractory prostate cancer. Rev Urol 9(Suppl 2):S13–S18

    PubMed  Google Scholar 

  4. Lu-Yao G, Moore DF, Oleynick JU et al (2007) Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol 177:535–539

    Article  PubMed  Google Scholar 

  5. Seidenfeld J, Samson DJ, Hasselblad V et al (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132:566–577

    PubMed  CAS  Google Scholar 

  6. Byar DP (1973) Proceeding: the veterans administration cooperative urological research group studies of cancer of the prostate. Cancer 32:1126–1130

    Article  PubMed  CAS  Google Scholar 

  7. Smith DC, Redman BG, Flaherty LE et al (1998) A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52:257–260

    Article  PubMed  CAS  Google Scholar 

  8. Hedlund PO, Henriksson P (2000) Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The scandinavian prostatic cancer group (SPCG)-5 trial study. Urology 55:328–333

    Article  PubMed  CAS  Google Scholar 

  9. Klotz L, McNeill I, Fleshner N (1999) A phase 1–2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 161:169–172

    Article  PubMed  CAS  Google Scholar 

  10. Klein D (1972) Treatment with estramustine phosphate in advanced prostatic cancer. Wien Med Wochenschr 122:458–460

    PubMed  CAS  Google Scholar 

  11. Hudes G (1997) Estramustine-based chemotherapy. Semin Urol Oncol 15:13–19

    PubMed  CAS  Google Scholar 

  12. Fizazi K, Le Maitre A, Hudes G et al (2007) Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8:994–1000

    Article  PubMed  CAS  Google Scholar 

  13. Tannock I, Gospodarowicz M, Meakin W et al (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597

    PubMed  CAS  Google Scholar 

  14. Venkitaraman R, Thomas K, Huddart RA et al (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101:440–443

    PubMed  CAS  Google Scholar 

  15. Nishimura K, Nonomura N, Yasunaga Y et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570–2576

    Article  PubMed  CAS  Google Scholar 

  16. Sartor O, Weinberger M, Moore A et al (1998) Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52:252–256

    Article  PubMed  CAS  Google Scholar 

  17. Trachtenberg J, Halpern N, Pont A (1983) Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 130:152–153

    PubMed  CAS  Google Scholar 

  18. Mahler C, Verhelst J, Denis L (1993) Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer 71:1068–1073

    Article  PubMed  CAS  Google Scholar 

  19. Nakabayashi M, Xie W, Regan MM et al (2006) Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107:975–981

    Article  PubMed  CAS  Google Scholar 

  20. Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025–1033

    Article  PubMed  CAS  Google Scholar 

  21. Nakabayashi M, Oh WK, Jacobus S et al (2010) Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int 105:1392–1396

    Article  PubMed  CAS  Google Scholar 

  22. Scholz M, Jennrich R, Strum S et al (2005) Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 173:1947–1952

    Article  PubMed  CAS  Google Scholar 

  23. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  24. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  PubMed  CAS  Google Scholar 

  25. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  26. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  27. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446

    Article  PubMed  CAS  Google Scholar 

  28. Attard G, Reid AH, Yap TA et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563–4571

    Article  PubMed  CAS  Google Scholar 

  29. Danila DC, Morris MJ, de Bono JS et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496–1501

    Article  PubMed  CAS  Google Scholar 

  30. Reid AH, Attard G, Danila DC et al (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489–1495

    Article  PubMed  CAS  Google Scholar 

  31. Attard G, Reid AH, A’Hern R et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742–3748

    Article  PubMed  CAS  Google Scholar 

  32. Hussain SA, James ND (2003) The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 4:489–497

    Article  PubMed  Google Scholar 

  33. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    Google Scholar 

  34. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073

    PubMed  Google Scholar 

  35. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15:2564–2569

    PubMed  CAS  Google Scholar 

  36. Von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608

    Article  PubMed  Google Scholar 

  37. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50–54

    Article  PubMed  CAS  Google Scholar 

  38. Stenzl A, Cowan NC, De Santis M et al (2009) The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 55:815–825

    Article  PubMed  Google Scholar 

  39. Dogliotti L, Carteni G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134–141

    Article  PubMed  CAS  Google Scholar 

  40. De Santis M, Bellmunt J, Mead G et al (2009) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II–results of EORTC study 30986. J Clin Oncol 27:5634–5639

    Article  PubMed  Google Scholar 

  41. Culine S, Theodore C, De Santis M et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395–1401

    Article  PubMed  CAS  Google Scholar 

  42. Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4461

    Article  PubMed  CAS  Google Scholar 

  43. Vishnu P, Mathew J, Tan WW (2011) Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 4:97–113

    PubMed  CAS  Google Scholar 

  44. Levi F, Ferlay J, Galeone C et al (2008) The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 101:949–958

    Article  PubMed  Google Scholar 

  45. Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132

    Article  PubMed  CAS  Google Scholar 

  46. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133–141

    Article  PubMed  CAS  Google Scholar 

  47. Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353:14–17

    Article  Google Scholar 

  48. Siebels M, Rohrmann K, Oberneder R et al (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 29:121–126

    Article  PubMed  CAS  Google Scholar 

  49. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  50. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  PubMed  CAS  Google Scholar 

  51. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590

    Article  PubMed  CAS  Google Scholar 

  52. Benedict A, Figlin RA, Sandstrom P et al (2011) Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int 108:665–672

    PubMed  Google Scholar 

  53. Herrmann E, Marschner N, Grimm MO et al (2011) Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol 29:361–366

    Article  PubMed  CAS  Google Scholar 

  54. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    Article  PubMed  Google Scholar 

  55. Escudier B, Bellmunt J, Negrier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150

    Article  PubMed  CAS  Google Scholar 

  56. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068

    Article  PubMed  CAS  Google Scholar 

  57. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    Article  PubMed  CAS  Google Scholar 

  58. Weikert S, Kempkensteffen C, Busch J et al (2011) Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World J Urol Apr 22 (Epub ahead of print)

  59. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456

    Article  PubMed  CAS  Google Scholar 

  60. Maclennan SJ, Maclennan SJ, Imamura M et al (2011) Urological cancer care pathways: development and use in the context of systematic reviews and clinical practice guidelines. World J Urol 29:291–301

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Faculté de Médecine Pierre et Marie Curie, University Paris VI, The Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Paris, France

    David R. Yates & Morgan Rouprêt

  2. Academic Urology Department, Hopital Pitié, 47-83 bvd l’Hopital, 75013, Paris, France

    Morgan Rouprêt

Authors
  1. David R. Yates
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morgan Rouprêt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morgan Rouprêt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yates, D.R., Rouprêt, M. Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World J Urol 31, 117–125 (2013). https://doi.org/10.1007/s00345-011-0798-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-011-0798-5

Keywords

Search

Navigation